CDKN2B-AS1 and ovarian cancer: In addition, we found ANRIL was higher and let-7a was lower in cisplatin-resistant cells (SKOV3/DDP) as compared with cisplatin-sensitive cells (SKOV3), suggesting that ANRIL may target let-7a to affect the cisplatin resistance of ovarian cancer cells.